Novartis Acquires Biotech Firm Excellergy to Strengthen Allergy Pipeline

Novartis has entered into a definitive agreement to acquire Excellergy, Inc., a private biotechnology company focused on immunology. The acquisition centers on Exl-111, a next-generation anti-IgE antibody currently in Phase 1 clinical trials. This drug candidate is designed to provide faster and more profound suppression of allergy pathways compared to existing conventional therapies. By integrating this asset, Novartis aims to solidify its global leadership in treating IgE-mediated diseases and food allergies. Fiona Marshall, President of Biomedical Research at Novartis, highlighted the strategic value of adding this high-affinity antibody to their pipeline. While the asset is in its early stages, the move represents a significant expansion into high-growth immunology markets.